Harnessing The Power Of Electronic Clinical Outcomes Assessments (eCOA) Technology

The consideration of incorporating digital technologies into rare disease studies, characterized by smaller patient cohorts, shifts the focus from return on investment (ROI) to the critical aspect of data integrity. In comparison to traditional paper-based patient reported outcomes (PROs), electronic modalities, or electronic clinical outcomes assessments (eCOA), offer a more easily demonstrable assurance of data integrity.

Following the widespread adoption of digitalized trials spurred by the COVID-19 pandemic, many studies are now designed with an emphasis on eCOAs. This preference is driven by the enhanced quality of data collection, especially within rare disease patient cohorts, allowing for greater innovation in defining endpoints. Beyond financial considerations, which often involve high costs for effective treatments, these trials are highly sought after by patient advocacy groups and research organizations, given the small yet influential market demand.

In the third installment of our annual C3 Summits held in London on September 13, industry experts and leaders gathered to discuss challenges, opportunities, and strategies in clinical trial diversity, centricity, and outcome assessments. This recap focuses on key insights from our COA-focused panel, titled "Harnessing the Power of eCOA Technology."